Symbols

UTHR

United Therapeutics·NASDAQ

--(--)

UTHR fundamentals

UTHR Q4 2025 Earnings

United Therapeutics (UTHR) released its earnings on Feb 25, 2026: revenue was 790.20M (YoY +7.38%), missed estimates; EPS was 7.7 (YoY +24.39%), beat estimates.

Revenue / YoY

790.20M

+7.38%

EPS / YoY

7.7

+24.39%

Report date

Feb 25, 2026

UTHR Earnings Call Summary for Q4,2025

2027 Product Breakthroughs: Launching three category-defining therapies addressing cough, dosing frequency, and IPF efficacy gaps.
Revenue Growth Track Record: $3B+ in 2025, 11% YoY growth, on track for $4B+ run rate by end-2027.
Market Leadership: Tyvaso DPI maintains 24% YoY growth despite competitor entry; Q4 referrals at pre-competitor levels.
Clinical Momentum: TETON 2 IPF trial showed 95.6mL FVC improvement; super prostacyclin unblinding imminent.

Earnings

EPS

Revenue

Revenue & Expenses

UTHR has released its 2025 Q4 earnings report, with revenue of 790.20M, reflecting a YoY change of 7.38%, and net profit of 364.30M, showing a YoY change of 20.91%. The Sankey diagram below clearly presents UTHR's revenue sources and cost distribution.

Key Indicators

United Therapeutics (UTHR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

United Therapeutics (UTHR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

United Therapeutics (UTHR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

United Therapeutics (UTHR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown